172 related articles for article (PubMed ID: 34968417)
21. Can immune responses predict which vaccines work best?
Cohen J
Science; 2021 Jul; 373(6551):142-143. PubMed ID: 34244387
[No Abstract] [Full Text] [Related]
22. Plasma Neutralization of the SARS-CoV-2 Omicron Variant.
Schmidt F; Muecksch F; Weisblum Y; Da Silva J; Bednarski E; Cho A; Wang Z; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
N Engl J Med; 2022 Feb; 386(6):599-601. PubMed ID: 35030645
[No Abstract] [Full Text] [Related]
23. COVID-19 vaccines for patients with haematological conditions.
Sun C; Pleyer C; Wiestner A
Lancet Haematol; 2021 May; 8(5):e312-e314. PubMed ID: 33811822
[No Abstract] [Full Text] [Related]
24. Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant.
Zhao X; Li D; Ruan W; Chen Z; Zhang R; Zheng A; Qiao S; Zheng X; Zhao Y; Dai L; Han P; Gao GF
N Engl J Med; 2022 Mar; 386(9):894-896. PubMed ID: 35081296
[No Abstract] [Full Text] [Related]
25. Audio Interview: How Well Are Covid-19 Vaccines Working?
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Jul; 385(2):e15. PubMed ID: 34233102
[No Abstract] [Full Text] [Related]
26. Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?
Terpos E; Trougakos IP; Karalis V; Ntanasis-Stathopoulos I; Sklirou AD; Bagratuni T; Papanagnou ED; Patseas D; Gumeni S; Malandrakis P; Korompoki E; Dimopoulos MA
Am J Hematol; 2021 Sep; 96(9):E321-E324. PubMed ID: 34028867
[No Abstract] [Full Text] [Related]
27. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen.
Keskin AU; Bolukcu S; Ciragil P; Topkaya AE
J Med Virol; 2022 Jan; 94(1):39-41. PubMed ID: 34536028
[No Abstract] [Full Text] [Related]
28. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.
Yalçın TY; Topçu DI; Doğan Ö; Aydın S; Sarı N; Erol Ç; Kuloğlu ZE; Azap ÖK; Can F; Arslan H
J Med Virol; 2022 Jan; 94(1):279-286. PubMed ID: 34468990
[TBL] [Abstract][Full Text] [Related]
29. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
[TBL] [Abstract][Full Text] [Related]
30. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM
Front Immunol; 2021; 12():728021. PubMed ID: 34646267
[TBL] [Abstract][Full Text] [Related]
31. Audio Interview: New Evidence on SARS-CoV-2 Vaccine Boosters.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Sep; 385(12):e48. PubMed ID: 34525292
[No Abstract] [Full Text] [Related]
32. Study Suggests Lasting Immunity After COVID-19, With a Big Boost From Vaccination.
Abbasi J
JAMA; 2021 Aug; 326(5):376-377. PubMed ID: 34259836
[No Abstract] [Full Text] [Related]
33. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.
Nemet I; Kliker L; Lustig Y; Zuckerman N; Erster O; Cohen C; Kreiss Y; Alroy-Preis S; Regev-Yochay G; Mendelson E; Mandelboim M
N Engl J Med; 2022 Feb; 386(5):492-494. PubMed ID: 34965337
[No Abstract] [Full Text] [Related]
34. SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons.
Rössler A; Riepler L; Bante D; von Laer D; Kimpel J
N Engl J Med; 2022 Feb; 386(7):698-700. PubMed ID: 35021005
[No Abstract] [Full Text] [Related]
35. Improved immunogenicity against SARS-CoV-2 in a solid-organ transplant recipient by switching vaccines.
Al Jalali V; Scherzer S; Zeitlinger M
Clin Microbiol Infect; 2021 Oct; 27(10):1529-1530. PubMed ID: 34192576
[No Abstract] [Full Text] [Related]
36. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.
Corbett KS; Nason MC; Flach B; Gagne M; O'Connell S; Johnston TS; Shah SN; Edara VV; Floyd K; Lai L; McDanal C; Francica JR; Flynn B; Wu K; Choi A; Koch M; Abiona OM; Werner AP; Moliva JI; Andrew SF; Donaldson MM; Fintzi J; Flebbe DR; Lamb E; Noe AT; Nurmukhambetova ST; Provost SJ; Cook A; Dodson A; Faudree A; Greenhouse J; Kar S; Pessaint L; Porto M; Steingrebe K; Valentin D; Zouantcha S; Bock KW; Minai M; Nagata BM; van de Wetering R; Boyoglu-Barnum S; Leung K; Shi W; Yang ES; Zhang Y; Todd JM; Wang L; Alvarado GS; Andersen H; Foulds KE; Edwards DK; Mascola JR; Moore IN; Lewis MG; Carfi A; Montefiori D; Suthar MS; McDermott A; Roederer M; Sullivan NJ; Douek DC; Graham BS; Seder RA
Science; 2021 Sep; 373(6561):eabj0299. PubMed ID: 34529476
[TBL] [Abstract][Full Text] [Related]
37. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost.
Ai J; Zhang H; Zhang Y; Lin K; Zhang Y; Wu J; Wan Y; Huang Y; Song J; Fu Z; Wang H; Guo J; Jiang N; Fan M; Zhou Y; Zhao Y; Zhang Q; Liu Q; Lv J; Li P; Qiu C; Zhang W
Emerg Microbes Infect; 2022 Dec; 11(1):337-343. PubMed ID: 34935594
[No Abstract] [Full Text] [Related]
38. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study.
Fendler A; Shepherd STC; Au L; Wilkinson KA; Wu M; Byrne F; Cerrone M; Schmitt AM; Joharatnam-Hogan N; Shum B; Tippu Z; Rzeniewicz K; Boos LA; Harvey R; Carlyle E; Edmonds K; Del Rosario L; Sarker S; Lingard K; Mangwende M; Holt L; Ahmod H; Korteweg J; Foley T; Bazin J; Gordon W; Barber T; Emslie-Henry A; Xie W; Gerard CL; Deng D; Wall EC; Agua-Doce A; Namjou S; Caidan S; Gavrielides M; MacRae JI; Kelly G; Peat K; Kelly D; Murra A; Kelly K; O'Flaherty M; Dowdie L; Ash N; Gronthoud F; Shea RL; Gardner G; Murray D; Kinnaird F; Cui W; Pascual J; Rodney S; Mencel J; Curtis O; Stephenson C; Robinson A; Oza B; Farag S; Leslie I; Rogiers A; Iyengar S; Ethell M; Messiou C; Cunningham D; Chau I; Starling N; Turner N; Welsh L; van As N; Jones RL; Droney J; Banerjee S; Tatham KC; O'Brien M; Harrington K; Bhide S; Okines A; Reid A; Young K; Furness AJS; Pickering L; Swanton C; ; Gandhi S; Gamblin S; Bauer DLV; Kassiotis G; Kumar S; Yousaf N; Jhanji S; Nicholson E; Howell M; Walker S; Wilkinson RJ; Larkin J; Turajlic S;
Nat Cancer; 2021 Dec; 2(12):1305-1320. PubMed ID: 35121899
[TBL] [Abstract][Full Text] [Related]
39. Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine.
Gavriatopoulou M; Terpos E; Malandrakis P; Ntanasis-Stathopoulos I; Briasoulis A; Gumeni S; Fotiou D; Papanagnou ED; Migkou M; Theodorakakou F; Eleutherakis-Papaiakovou E; Kanellias N; Trougakos IP; Kastritis E; Dimopoulos MA
Br J Haematol; 2022 Jan; 196(2):356-359. PubMed ID: 34528249
[TBL] [Abstract][Full Text] [Related]
40. Audio Interview: Monoclonal Antibodies and Vaccine Boosts.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Jul; 385(3):e18. PubMed ID: 34260844
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]